Literature DB >> 10899253

Induced sputum examination: diagnosis of pulmonary involvement in Fabry's disease.

M M Kelly1, R Leigh, R McKenzie, D Kamada, E H Ramsdale, F E Hargreave.   

Abstract

Fabry's disease is a rare inherited metabolic disorder caused by a deficiency in the enzyme alpha-galactosidase A. It can affect almost every organ, including the lungs. Confirmation of lung involvement has depended on invasive bronchial biopsy specimens or brushings to confirm the presence of typical lamellar inclusion bodies within bronchial epithelial cells. We report a patient with known Fabry's disease in whom these inclusion bodies were identified by examination of induced sputum.

Entities:  

Mesh:

Year:  2000        PMID: 10899253      PMCID: PMC1745834          DOI: 10.1136/thorax.55.8.720

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  8 in total

1.  Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease.

Authors:  Gregory Bierer; David Balfe; William R Wilcox; Zab Mosenifar
Journal:  J Inherit Metab Dis       Date:  2006-08       Impact factor: 4.982

2.  Clinical expert panel on monitoring potential lung toxicity of inhaled oligonucleotides: consensus points and recommendations.

Authors:  Eric W Alton; Homer A Boushey; Holger Garn; Francis H Green; Michael Hodges; Richard J Martin; Robert D Murdoch; Harald Renz; Stephen B Shrewsbury; Rosanne Seguin; Graham Johnson; Joel D Parry; Jeff Tepper; Paolo Renzi; Joy Cavagnaro; Nicolay Ferrari
Journal:  Nucleic Acid Ther       Date:  2012-07-18       Impact factor: 5.486

3.  Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.

Authors:  R Y Wang; J T Abe; A H Cohen; W R Wilcox
Journal:  J Inherit Metab Dis       Date:  2008-10-21       Impact factor: 4.982

4.  Natural history of the respiratory involvement in Anderson-Fabry disease.

Authors:  S Magage; J-C Lubanda; Z Susa; J Bultas; D Karetová; R Dobrovolný; M Hrebícek; D P Germain; A Linhart
Journal:  J Inherit Metab Dis       Date:  2007-07-09       Impact factor: 4.982

5.  Long-term follow-up of pulmonary function in Fabry disease: A bi-center observational study.

Authors:  Daniel P Franzen; Albina Nowak; Sarah R Haile; Dominique Mottet; Marco Bonani; Olivier Dormond; Malcolm Kohler; Pierre A Krayenbuehl; Frederic Barbey
Journal:  PLoS One       Date:  2017-07-25       Impact factor: 3.240

6.  Serial Analysis of Cardiopulmonary Fitness and Echocardiography in Patients with Fabry Disease Undergoing Enzyme Replacement Therapy.

Authors:  Sheng-Hui Tuan; Pao-Chin Chiu; I-Hsiu Liou; Wen-Hsien Lu; Hung-Ya Huang; Shin-Yi Wu; Guan-Bo Chen; Ko-Long Lin
Journal:  J Rehabil Med Clin Commun       Date:  2020-02-27

Review 7.  Fabry disease, respiratory symptoms, and airway limitation - a systematic review.

Authors:  Camilla Kara Svensson; Ulla Feldt-Rasmussen; Vibeke Backer
Journal:  Eur Clin Respir J       Date:  2015-06-26

8.  Pulmonary involvement in Fabry disease: effect of plasma globotriaosylsphingosine and time to initiation of enzyme replacement therapy.

Authors:  Daniel Franzen; Sarah R Haile; David C Kasper; Thomas P Mechtler; Andreas J Flammer; Pierre A Krayenbühl; Albina Nowak
Journal:  BMJ Open Respir Res       Date:  2018-04-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.